A non-interventional observational study in adults assessing the safety and tolerability of AVANZ® in case of concomitant specific immunotherapy (SCIT/AIT/SLIT)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005030

Enrollment

300

Registered

2013-05-28

Start date

2012-09-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J30.1 J30.3

Interventions

Group 1: routine treatment with subcutaneous specific immunotherapy (SCIT, AVANZ®) and concomitant further specific immunotherapy, documentation of tolerability

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Routine treatment with subcutaneous specific immunotherapy (AVANZ®) and concomitant treatment with further specific immunotherapy

Exclusion criteria

Exclusion criteria: Contraindications of specific immunotherapy

Design outcomes

Primary

Measure	Time frame
Frequency and type of adverse events recorded by the physician during administration of subcutaneous injections and in patient diaries coded acc. to MedDRA for the first 4 months of treatment	—

Secondary

Measure	Time frame
Global assessment of tolerability by patient and physician after 4 months of treatment	—

Countries

Germany

Contacts

Public ContactHendrik Wolf

ALK-Abelló Arzneimittel GmbH, Clinical Development

hendrik.wolf@alk.net+49 40 703845-342

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026